Department of Radiation Oncology, Institut Curie, Paris, France.
Radiother Oncol. 2010 Mar;94(3):300-6. doi: 10.1016/j.radonc.2009.12.043. Epub 2010 Feb 18.
To evaluate the dosimetry of helical tomotherapy (HT) and three-dimensional conformal radiotherapy (3D-CRT) in breast cancer patients undergoing whole breast radiation with simultaneous integrated boost (SIB) of the tumor bed.
Thirteen patients with breast cancer treated by lumpectomy and requiring whole breast radiotherapy with tumor bed boost were planned using both HT and 3D-CRT using the field-in-field technique. The whole breast and tumor bed were prescribed 50.68 Gy and 64.4 Gy, respectively, in 28 fractions. Dosimetries for both techniques were compared.
Coverage of the whole breast was adequate with both techniques (V(95%)=96.22% vs. 96.25%, with HT and 3D-CRT, respectively; p=0.64). Adequate tumor bed coverage was also achieved, although it was significantly lower with HT (V(95%)=97.18% vs. 99.72%; p<0.001). Overdose of the breast volume outside the tumor bed was significantly lower with HT (V(54.23 Gy)=12.47% vs. 30.83%; p<0.001). Ipsilateral lung V(20 Gy) (6.34% vs. 10.17%; p<0.001), V(5 Gy) (16.54% vs. 18.53%; p<0.05) and mean dose (4.05 Gy vs. 6.36 Gy; p<0.001) were significantly lower with HT. In patients with left-sided tumors, heart V(30 Gy) (0.03% vs. 1.14%; p<0.05) and mean dose (1.35 Gy vs. 2.22 Gy; p<0.01) were significantly lower with HT, but not V(5 Gy). Contralateral breast V(5 Gy) (0.27% vs. 0.00%; p<0.01) and maximum dose were significantly increased with HT.
In breast cancer treated with SIB, both HT and 3D-CRT provided adequate target volume coverage and low heart doses. Tumor bed coverage was slightly lower with HT, but HT avoided unnecessary breast overdosage while improving ipsilateral lung dosimetry.
评估螺旋断层放疗(HT)和三维适形放疗(3D-CRT)在接受全乳照射和肿瘤床同步整合加量(SIB)的乳腺癌患者中的剂量学。
对 13 例接受保乳手术并需要全乳放疗和肿瘤床加量的乳腺癌患者,分别采用 HT 和 3D-CRT 场中场技术进行计划。全乳和肿瘤床分别规定为 50.68 Gy 和 64.4 Gy,共 28 次。比较两种技术的剂量学。
两种技术均能充分覆盖全乳(V(95%)=96.22%与 96.25%,HT 和 3D-CRT 分别;p=0.64)。肿瘤床的覆盖也足够,但 HT 略低(V(95%)=97.18%与 99.72%;p<0.001)。HT 可显著降低肿瘤床外乳房体积的高剂量(V(54.23 Gy)=12.47%与 30.83%;p<0.001)。同侧肺 V(20 Gy)(6.34%与 10.17%;p<0.001)、V(5 Gy)(16.54%与 18.53%;p<0.05)和平均剂量(4.05 Gy 与 6.36 Gy;p<0.001)均显著降低。左侧肿瘤患者的心脏 V(30 Gy)(0.03%与 1.14%;p<0.05)和平均剂量(1.35 Gy 与 2.22 Gy;p<0.01)也显著降低,但 V(5 Gy)无差异。对侧乳房 V(5 Gy)(0.27%与 0.00%;p<0.01)和最大剂量明显增加。
在接受 SIB 的乳腺癌患者中,HT 和 3D-CRT 均能充分覆盖靶区,且心脏剂量低。HT 肿瘤床覆盖略低,但可避免不必要的乳房高剂量,同时改善同侧肺剂量学。